Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

Company Overview

Adverum Biotechnologies is a clinical-stage gene therapy company focused on the discovery, development and delivery of novel treatments for ocular and rare diseases. Utilizing adeno-associated virus (AAV)–based vectors, the company seeks to deliver long-lasting, one-time therapies designed to address underlying genetic causes of vision loss and other conditions. Its proprietary platform combines engineering of AAV capsids for targeted tissue tropism with optimized expression cassettes, aiming to improve safety and durability over current standards of care.

The company’s lead programs target retinal disorders, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy, through intravitreal administration of AAV vectors expressing therapeutic proteins. Key pipeline candidates include ADVM-022, which delivers a gene encoding an anti-VEGF molecule, and ADVM-043, a next-generation vector designed for broad ocular neovascular indications. Preclinical efforts also explore additional ophthalmic and rare disease targets, leveraging Adverum’s vector design expertise to expand into conditions with significant unmet medical need.

Adverum conducts research and clinical development primarily in the United States, with trial sites and regulatory engagement extending into Europe and other regions. The company collaborates with academic institutions, contract research organizations and strategic partners to advance its programs through Phase 1 and Phase 2 studies. Manufacturing and supply chain activities are supported by external GMP-compliant facilities, enabling scalable vector production for both clinical and future commercial use.

Founded in 2006 (formerly known as Avalanche Biotechnologies), Adverum Biotechnologies has evolved through multiple financing rounds and a 2019 corporate rebranding to reflect its broadened gene therapy ambitions. The company is led by President and Chief Executive Officer Adie Kim, whose background in specialty pharmaceuticals and biotech supports Adverum’s transition from early research to late-stage clinical development. Through its focused platform and strategic collaborations, Adverum aims to deliver durable, potentially curative treatments that could transform care for patients with vision disorders and other genetic diseases.

Key Stats

• Today's Range: $4.36 to $4.36
• 50-Day Range: $4.09 to $4.36
• 52-Week Range: $1.78 to $5.75
• Volume: N/A
• Average Volume: 452,470 shs
• Market Capitalization: $96.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.88
• Consensus Rating: Hold

Adverum Biotechnologies Stock Analysis - MarketRank™

Adverum Biotechnologies scored higher than 11% of companies evaluated by MarketBeat, and ranked 847th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Hold

Consensus Rating

Adverum Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Adverum Biotechnologies has a consensus price target of $4.88, representing about 11.8% upside from its current price of $4.36.

Amount of Analyst Coverage

Adverum Biotechnologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adverum Biotechnologies is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adverum Biotechnologies is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adverum Biotechnologies has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ADVM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adverum Biotechnologies does not currently pay a dividend.

Dividend Growth

Adverum Biotechnologies does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for ADVM on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adverum Biotechnologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.00% of the stock of Adverum Biotechnologies is held by insiders.

Percentage Held by Institutions

48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2025
• Today: 10/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ADVM
• CIK: 1501756
• Web: www.adverum.com
• Phone: (650) 656-9323
• Fax: 650-329-8151
• Employees: 190
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Adverum Biotechnologies: $4.88
• High Price Target: $5.50
• Low Price Target: $4.00
• Potential Upside/Downside: +11.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.93 million
• Net Margins: N/A
• Pretax Margin: -16,949.20%
• Return on Equity: -3,476.17%
• Return on Assets: -152.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.65
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.40 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 22,077,000
• Free Float: 20,752,000
• Market Cap: $96.26 million
• Optionable: Optionable
• Beta: 0.87